Registry for Posterior Reversible Encephalopathy Syndrome in critically ill patients
Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients
Ictal Group · NCT03470467
This study collects information about patients with Posterior Reversible Encephalopathy Syndrome in intensive care to better understand their symptoms, treatments, and recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ictal Group (other) |
| Locations | 1 site (Le Chesnay) |
| Trial ID | NCT03470467 on ClinicalTrials.gov |
What this trial studies
This observational registry collects data on patients diagnosed with Posterior Reversible Encephalopathy Syndrome (PRES) in intensive care units. It aims to gather comprehensive information regarding the onset, clinical features, treatments, and outcomes of PRES. Data will include demographic details, clinical findings, imaging results, and treatment timelines, with follow-up assessments at various intervals post-discharge. The study does not involve any interventions but focuses on understanding the condition through detailed data collection.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been diagnosed with PRES and are admitted to an intensive care unit.
Not a fit: Patients with normal cerebral imaging will not benefit from this study as they do not meet the criteria for PRES.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of PRES, leading to improved diagnosis and management strategies for affected patients.
How similar studies have performed: While this approach is observational and may not have direct precedents, similar registries have successfully contributed to understanding other critical conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>= 18 years * Posterior Reversible Encephalopathy Syndrome defined as: * combination of consciousness impairment, seizure activity, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs AND * cerebral imaging abnormalities involving the white matter (brain CT scan hypodensities AND/OR Brain MRI hypoT1, hyper T2 FLAIR) * intensive care unit admission Exclusion Criteria: * normal cerebral imaging
Where this trial is running
Le Chesnay
- Intensive Care Unit - Versailles Hospital — Le Chesnay, France (RECRUITING)
Study contacts
- Principal investigator: Stephane LEGRIEL, MD — Ictal Group
- Study coordinator: Stephane LEGRIEL, MD
- Email: slegriel@ch-versailles.fr
- Phone: +33139639717
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Posterior Reversible Encephalopathy Syndrome